Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer.
Semin Oncol
; 19(3 Suppl 9): 53-8, 1992 Jun.
Article
em En
| MEDLINE
| ID: mdl-1641658
ABSTRACT
Hydroxyurea is an active single agent in squamous cell cancer of the head and neck. It has been used clinically, most frequently as a radiation-enhancing agent with concomitant radiotherapy. Pilot trials testing hydroxyurea in this setting reported encouraging results. Two randomized trials have been conducted with inconclusive results, possibly relating to study cohort size and short period of follow-up. More recently, hydroxyurea has been investigated with 5-fluorouracil and concomitant radiotherapy. A sound theoretic rationale can be made for this approach and data derived from a phase I/II study are presented. These support the further investigation of this regimen.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Radiossensibilizantes
/
Carcinoma de Células Escamosas
/
Fluoruracila
/
Neoplasias de Cabeça e Pescoço
/
Hidroxiureia
Tipo de estudo:
Clinical_trials
Limite:
Humans
Idioma:
En
Ano de publicação:
1992
Tipo de documento:
Article